Showing 2101-2110 of 3303 results for "".
Charging Toward Stage 2 of Meaningful Use
https://practicaldermatology.com/topics/practice-management/charging-toward-stage-2-of-meaningful-use/21467/As the next stage of the Federal EHR incentive program is set to begin, the forecast remains uncertain.SPF Recommendations: Should They Change?
https://practicaldermatology.com/topics/skin-cancer-photoprotection/spf-recommendations-should-they-change/21475/What is the minimum SPF dermatologists should be recommending to their patients?Protect Yourself Against System Breaches and Errors
https://practicaldermatology.com/topics/practice-management/protect-yourself-against-system-breaches-and-errors/21579/New reports of cyber-terrorism highlight the importance of EHR security.New Products and Pharmacologic Developments
https://practicaldermatology.com/columns/new-products/new-products-and-pharmacologic-developments/21633/An Overview of Topical Therapies for Managing Pediatric AD
https://practicaldermatology.com/topics/atopic-dermatitis/an-overview-of-topical-ththerapies-for-managing-pediatric-ad/54375/Moisturization is foundational in AD management; no specific formulation has demonstrated superiority, and excessive bathing may worsen disease via increased transepidermal water loss. Topical corticosteroids and calcineurin inhibitors remain first-line due to strong efficacy data, cost-effectiveneAdvanced Management Solutions for High-Grade Cutaneous Toxicities to Cancer Therapy
https://practicaldermatology.com/topics/skin-cancer-photoprotection/advanced-management-solutions-for-high-grade-cutaneous-toxicities-to-cancer-therapy/57176/The emergence of immune checkpoint inhibitors (ICIs) has fundamentally altered the prognosis for patients with advanced skin malignancies, yet the high incidence of cutaneous immune-related adverse events (irAEs) remains a significant barrier to treatment continuity. Here, we review the clinical manRecent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20371/Beyond the Flare: Choosing the Right Systemic in Moderate-to-Severe Atopic Dermatitis
https://practicaldermatology.com/videos/dermatology-hub-neuroimmune-network/beyond-the-flare-choosing-the-right-systemic-in-moderate-to-severe-atopic-dermatitis/39728/New in My Practice: OTC Skincare/New Products
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-in-my-practice-otc-skincarenew-products/23704/The Role for Rinvoq in AD Care
https://practicaldermatology.com/topics/atopic-dermatitis/the-role-for-rinvoq-in-ad-care/23663/One of the first oral JAK inhibitors approved in dermatology expands options for moderate to severe AD.